Source:http://linkedlifedata.com/resource/pubmed/id/10152782
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1996-1-19
|
| pubmed:abstractText |
A retrospective, cost-effectiveness analysis was performed on 106 clinically evaluable patients who participated in a multi-centre, randomized study of sequential IV/oral ciprofloxacin therapy versus ceftazidime for the treatment of nosocomial pneumonia. Although nearly half of the ciprofloxacin patients received sequential therapy, the majority were treated with a full IV regimen. Clinical success rates and antibiotic-related adverse events were similar for the ciprofloxacin and ceftazidime groups. Per patient and per day costs of antibiotic acquisition; preparation and administration; treatment of adverse events, and clinical failures were compared. Decision analysis revealed that ciprofloxacin therapy was cost-effective compared to ceftazidime 2 g q8h. Varying the probability of clinical success between 60-99% failed to change the economic decision; costs for ciprofloxacin were always lower than for ceftazidime. Further sensitivity analyses demonstrated that if the ceftazidime price was reduced by 50% (equivalent to 1 g q8h), treatment costs would be similar to ciprofloxacin therapy. Increasing the ciprofloxacin price by 50% (equivalent to a q8h frequency) produced per patient costs similar to ceftazidime, although ciprofloxacin therapy retained a lower cost per day (p < 0.0002). For the treatment of nosocomial pneumonia, ciprofloxacin therapy was cost-effective compared to ceftazidime.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
H
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0008-4123
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
48
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
276-83
|
| pubmed:dateRevised |
2009-10-12
|
| pubmed:meshHeading |
pubmed-meshheading:10152782-Administration, Oral,
pubmed-meshheading:10152782-Adult,
pubmed-meshheading:10152782-Aged,
pubmed-meshheading:10152782-Aged, 80 and over,
pubmed-meshheading:10152782-Anti-Bacterial Agents,
pubmed-meshheading:10152782-Canada,
pubmed-meshheading:10152782-Ceftazidime,
pubmed-meshheading:10152782-Ciprofloxacin,
pubmed-meshheading:10152782-Cost-Benefit Analysis,
pubmed-meshheading:10152782-Cross Infection,
pubmed-meshheading:10152782-Drug Costs,
pubmed-meshheading:10152782-Female,
pubmed-meshheading:10152782-Humans,
pubmed-meshheading:10152782-Infusions, Intravenous,
pubmed-meshheading:10152782-Male,
pubmed-meshheading:10152782-Middle Aged,
pubmed-meshheading:10152782-Pharmacy Service, Hospital,
pubmed-meshheading:10152782-Pneumonia,
pubmed-meshheading:10152782-Retrospective Studies,
pubmed-meshheading:10152782-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia.
|
| pubmed:affiliation |
School of Pharmacy, University of New York at Buffalo, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|